Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies-an update

被引：8

作者：

Donoghue, S ^{[1
]}

Greenlees, C ^{[1
]}

机构：

[1] Elan Pharmaceut, Letchworth, Herts, England

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2000年 / 9卷 / 01期

关键词：

clinical trials; beta-interferon; multiple sclerosis; new treatments;

D O I：

10.1517/13543784.9.1.167

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the past few years there has been significant progress in the development of therapy for the treatment of relapsing remitting and secondary progressive multiple sclerosis. Research interest in multiple sclerosis (MS) therapeutics has remained high and clinical investigation into potential new therapies continues. This review summarises the advances with currently available therapies and briefly outlines the results from studies with other drugs being developed for the treatment of multiple sclerosis.

引用

页码：167 / 171

页数：5

共 12 条

[1] Intravenous immunoglobulin treatment in multiple sclerosis - Effect on relapses [J].

Achiron, A ;

Gabbay, U ;

Gilad, R ;

Hassin-Baer, S ;

Barak, Y ;

Gornish, M ;

Elizur, A ;

Goldhammer, Y ;

Sarova-Pinhas, I .

NEUROLOGY, 1998, 50 (02) :398-402

[2]

BLUMHARDT L, 1990, EUR NEUR SOC 9 M JUN

[3] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[4]

HARTUNG HP, 1998, MULT SCLER, V4, P325

[5] Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis [J].

Kappos, L ;

Polman, C ;

Pozzilli, C ;

Thompson, A ;

Dahlke, F ;

Knight, R ;

Hern, J ;

Coleman, R ;

Gerrie, L ;

Cooper, G ;

Moore, J ;

Boringa, J ;

van Oosten, B ;

Ronner, H ;

Schrijver, H ;

Truyen, L ;

Montalbán, J ;

Río, J ;

Tintoré, M ;

Jacas, C ;

Marzo, E ;

Lechner-Scott, J ;

Huber, S ;

Lienert, C ;

Brunnschweiler, H ;

Hawkins, S ;

Droogan, A ;

McDonnell, G ;

Duddy, M ;

McKinstry, S ;

Altenkirch, H ;

Baum, K ;

Einhäupl, K ;

Marx, P ;

Poewe, W ;

Walter, G ;

Akman, H ;

Brockmeier, B ;

Scherer, P ;

Zschenderlein, R ;

Schmierer, K ;

Gelderblom, H ;

Hartmann, A ;

Stapf, C ;

Lüschow, A ;

Mackert, B ;

Schumacher, H ;

Masuhr, F ;

Hempel, T ;

Zimmermann, R .

LANCET, 1998, 352 (9139) :1491-1497

[6]

KRAPF H, 1998, MULT SCLER, V4, P380

[7]

LEARY SM, 1997, J NEUROL S3, V244, P563

[8]

LUBLIN F, 1999, NEUROLOGY S2, V52

[9]

Rice G, 1998, ANN NEUROL, V44, P504

[10] A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis [J].

Romine, JS ;

Sipe, JC ;

Koziol, JA ;

Zyroff, J ;

Beutler, E .

PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1999, 111 (01) :35-44

← 1 2 →